LGALS3
Galectin-3
Also known as: GALIG, LEG3_HUMAN, LGALS2, MAC-2
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P17931
- Gene
- LGALS3
- Ensembl
- ENSG00000131981
- Chromosome
- 14
- Canonical length
- 250 aa
- Protein class
- Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins
- Subcellular location
- Nucleoplasm,Plasma membrane,Cytosol
- Secretome location
- Secreted to blood
OverviewNCBI Gene
This gene encodes a member of the galectin family of carbohydrate binding proteins. Members of this protein family have an affinity for beta-galactosides. The encoded protein is characterized by an N-terminal proline-rich tandem repeat domain and a single C-terminal carbohydrate recognition domain. This protein can self-associate through the N-terminal domain allowing it to bind to multivalent saccharide ligands. This protein localizes to the extracellular matrix, the cytoplasm and the nucleus. This protein plays a role in numerous cellular functions including apoptosis, innate immunity, cell adhesion and T-cell regulation. The protein exhibits antimicrobial activity against bacteria and fungi. Alternate splicing results in multiple transcript variants.[provided by RefSeq, Oct 2014]
Canonical amino-acid sequenceUniProt
250 residues, UniProt reviewed canonical sequence.
>P17931|LGALS3
1 MADNFSLHDA LSGSGNPNPQ GWPGAWGNQP AGAGGYPGAS YPGAYPGQAP PGAYPGQAPP
61 GAYPGAPGAY PGAPAPGVYP GPPSGPGAYP SSGQPSATGA YPATGPYGAP AGPLIVPYNL
121 PLPGGVVPRM LITILGTVKP NANRIALDFQ RGNDVAFHFN PRFNENNRRV IVCNTKLDNN
181 WGREERQSVF PFESGKPFKI QVLVEPDHFK VAVNDAHLLQ YNHRVKKLNE ISKLGISGDI
241 DLTSASYTMILocalizationUniProt · AlphaFold · HPA
Whether an antibody against LGALS3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.47
- Highest tissue expression
- 1,119 nTPM
Expression across tissuesHPA
Tissue
- colon: 1,119 nTPM
- rectum: 822 nTPM
- small intestine: 804 nTPM
- duodenum: 651 nTPM
- skin: 609 nTPM
- adipose tissue: 519 nTPM
Single-cell type
- colonocytes: 6,456 nCPM
- enterocytes: 4,004 nCPM
- esophageal apical cells: 3,990 nCPM
- enteric transient amplifying cells: 2,415 nCPM
- decidual stromal cells: 2,188 nCPM
- salivary duct cells: 1,972 nCPM
Immune cell
- classical monocyte: 653 nTPM
- intermediate monocyte: 545 nTPM
- total PBMC: 450 nTPM
- non-classical monocyte: 444 nTPM
- myeloid DC: 398 nTPM
- T-reg: 253 nTPM
Brain region
- thalamus: 68 nTPM
- cerebral cortex: 54 nTPM
- medulla oblongata: 52 nTPM
- white matter: 40 nTPM
- midbrain: 37 nTPM
- amygdala: 36 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about LGALS3.
Disease | AutoantibodyPubMed
Conditions in which antibodies against LGALS3 are reported. Each links to that disease's full target list.
Showing 1 of 2 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for LGALS3 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
16 publications
- Identification of galectin-3 as an autoantigen in patients with IgG4-related disease.
2019 · J Allergy Clin Immunol · RCR 6.1 · 122 citations - Disease Severity Linked to Increase in Autoantibody Diversity in IgG4-Related Disease.
2020 · Arthritis Rheumatol · RCR 3.2 · 54 citations - Blood-brain barrier dysfunction in immuno-mediated neurological diseases.
2018 · Immunol Med · RCR 2.8 · 58 citations - Galectin-3 and prohibitin 1 are autoantigens in IgG4-related cholangitis without clear-cut protective effects against toxic bile acids.
2023 · Front Immunol · RCR 2.3 · 11 citations - Identification of galectin-3 as a possible antibody target for secondary progressive multiple sclerosis.
2017 · Mult Scler · RCR 1.4 · 34 citations
Show 11 more
- Association of anti-acidic ribosomal protein P0 and anti-galectin 3 antibodies with the development of skin lesions in systemic lupus erythematosus.
2015 · Arthritis Rheumatol · RCR 1.3 · 34 citations - Identification of autoantibodies associated with systemic lupus erythematosus.
2002 · Biochem Biophys Res Commun · RCR 1.2 · 55 citations - Anti-Galectin-3 IgG autoantibodies in patients with Crohn's disease characterized by means of phage display peptide libraries.
2001 · J Clin Immunol · RCR 0.9 · 35 citations - Characterization of autoantibodies and cytokines related to cutaneous lupus erythematosus.
2021 · Lupus · RCR 0.5 · 8 citations - Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes.
2016 · PLoS One · RCR 0.5 · 11 citations - Anti-galectin-3 antibodies induce skin vascular inflammation via promoting local production of IL-1β in systemic lupus erythematosus.
2022 · Int Immunopharmacol · RCR 0.5 · 5 citations - Evidence for IgG autoantibodies to galectin-3, a beta-galactoside-binding lectin (Mac-2, epsilon binding protein, or carbohydrate binding protein 35) in human serum.
1995 · J Clin Immunol · RCR 0.4 · 16 citations - Diminished Expression of Galectin-3 Around Blisters in Bullous Pemphigoid: An Immunohistochemistry Study.
2020 · Dermatol Pract Concept · RCR 0.3 · 5 citations - Immunohistochemical Expression of Galectin-3 in Pemphigus Vulgaris.
2021 · Am J Dermatopathol · RCR 0.3 · 3 citations - Serum Anti-Gal-3 Autoantibody is a Predictive Marker of the Efficacy of Platinum-Based Chemotherapy against Pulmonary Adenocarcinoma.
2015 · Asian Pac J Cancer Prev · RCR 0.2 · 4 citations - Neutrophils impaired by anti-galectin-3 antibodies elicit inflammation of endothelial cells to aggregate the development of lupus cutaneous vasculitis.
2024 · Clin Exp Rheumatol · RCR 0.2 · 1 citations
Reference: T cellIEDB
1 publication
- Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens.
2024 · Blood · RCR 1.5 · 14 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.43
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.33
- DepMap mean gene effect
- -0.01
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- eosinophil chemotaxis
- epithelial cell differentiation
- innate immune response
- macrophage chemotaxis
- monocyte chemotaxis
- mononuclear cell migration
- mRNA processing
- negative regulation of endocytosis
- negative regulation of extrinsic apoptotic signaling pathway
- negative regulation of immunological synapse formation
- negative regulation of NK T cell activation
- negative regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell
- negative regulation of T cell receptor signaling pathway
- neutrophil chemotaxis
- positive chemotaxis
- positive regulation of calcium ion import
- positive regulation of mononuclear cell migration
- positive regulation of protein localization to plasma membrane
- positive regulation of protein-containing complex assembly
- regulation of extrinsic apoptotic signaling pathway via death domain receptors
- regulation of T cell apoptotic process
- regulation of T cell proliferation
- RNA splicing
Molecular functions
- carbohydrate binding
- chemoattractant activity
- disaccharide binding
- IgE binding
- laminin binding
- molecular condensate scaffold activity
- protein phosphatase binding
- protein phosphatase inhibitor activity
- receptor ligand inhibitor activity
- RNA binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of LGALS3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads LGALS3 as an antibody target. Whether an autoantibody or antibody against LGALS3 could matter depends on whether native LGALS3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
LGALS3 is annotated as secreted, so native LGALS3 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label LGALS3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...